Ascendis Pharma A-S

Ascendis Pharma A-S

Yahoo Finance • 20 days ago

Ascendis Pharma (ASND) Authorizes $400M Share Buyback

On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what... Full story

Yahoo Finance • 22 days ago

Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in... Full story

Yahoo Finance • 24 days ago

Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collabo... Full story

Yahoo Finance • 26 days ago

Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 26 days ago

Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback

Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 26 days ago

Ascendis Pharma sets $400M stock buyback plan

* Ascendis Pharma (ASND [https://seekingalpha.com/symbol/ASND]) board has authorized the company to repurchase up to $400M of its ordinary shares. * The program [https://seekingalpha.com/pr/20650409-ascendis-announces-planned-400-milli... Full story

Yahoo Finance • 27 days ago

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Ascendis Pharma - All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and c... Full story

Yahoo Finance • 29 days ago

BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis's achon... Full story

Yahoo Finance • last month

Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC

Company Logo Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the... Full story

Yahoo Finance • last month

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Ascendis Pharma COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Con... Full story

Yahoo Finance • last month

BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged... Full story

Yahoo Finance • last month

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

European equities traded in the US as American depositary receipts opened the week slightly lower la PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls

First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as comp... Full story

Yahoo Finance • 2 months ago

Stocks See Support from Favorable PPI Report

The S&P 500 Index ($SPX) (SPY) is up +0.57%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.22%.  September E-mini S&P futures (ESU26) are up +0.58%, and September E-mini Nasdaq... Full story

Yahoo Finance • 2 months ago

Stocks Settle Lower as Middle East Tensions Rise

The S&P 500 Index ($SPX) (SPY) closed down -0.18% on Thursday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.85%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.39%.  September E-mini S&P futures (ESU26) fell -0.18%,... Full story

Yahoo Finance • 3 months ago

European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Big Pharma Has a Case of Merger Mania

In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Tyler Crowe, Matt Frankel, and Lou Whiteman take a dive into what’s driving the merger-and-acquisition frenzy, including: Big pharma is using big wallets for M... Full story

Yahoo Finance • 4 months ago

Ascendis Pharma added to Russell 3000, Russell 1000 and other U.S. indexes

Ascendis Pharma (ASND [https://seekingalpha.com/symbol/ASND]) said [https://seekingalpha.com/pr/20565715-ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1000-russell] on Friday it was added to the Russell 300... Full story

Yahoo Finance • 4 months ago

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Ru... Full story

Yahoo Finance • 4 months ago

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GL... Full story